We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04074408
Recruitment Status : Recruiting
First Posted : August 30, 2019
Last Update Posted : May 26, 2020
Sponsor:
Collaborators:
The First Affiliated Hospital, University of Science and Technology of China
Huzhou Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Fujian Medical University
Jinhua Hospital, School of Medicine, Zhejiang University
Taizhou Hospital
Information provided by (Responsible Party):
Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A study to examine the safety and potential effectiveness of human umbilical cord mesenchymal stem cells (hUMSCs) in adults who have suffered spontaneous cerebral hemorrhage in basal ganglia. The hypothesis is that hUMSCs will be safe and can improve neurological function after intracerebral hemorrhage so that improve the prognosis of patients.

Condition or disease Intervention/treatment Phase
Basal Ganglia Hematoma Procedure: stereotactic surgery Biological: hUMSCs Biological: placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description: The hUMSCs suspension and placebo solvent have different appearance so only the participants but not the researches can be masked.
Primary Purpose: Treatment
Official Title: Intracavitary Injection of Human Umbilical Cord Mesenchymal Stem Cells in Acute Basal Ganglia Hematoma After Stereotactic Aspiration: a Randomized, Single-blind, Placebo-Controlled, Phase 2 Trial
Estimated Study Start Date : May 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cohort 1
low dose hUMSCs or high dose hUMSCs
 Procedure: stereotactic surgery
stereotactic aspiration surgery

Biological: hUMSCs
single intracavitary infusion 1 day after stereotactic aspiration surgery
Experimental: Cohort 2
best dose of hUMSCs (from cohort 1) or placebo
 Procedure: stereotactic surgery
stereotactic aspiration surgery

Biological: hUMSCs
single intracavitary infusion 1 day after stereotactic aspiration surgery

Biological: placebo
single intracavitary infusion 1 day after stereotactic aspiration surgery


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Frequency of dose limiting adverse events [ Time Frame: 3 days ]
  2. Modified Rankin Scale (mRS) to measure the prognosis [ Time Frame: 3 months ]
    The Modified Rankin Scale (mRS) measures independence rather than performance of specific tasks. Scale consists of six grades from 0 to 5; 0 denotes no symptoms and 5 indicates severe disability. For clinical purpose, mild disability range is from 0 to 2; moderate disability ranges from 3 to 4 and 5 indicates severe disability.

  3. National institute of Health Stroke Scale (NIHSS) to measure stroke recovery [ Time Frame: 3 months ]
    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item impairment scale used to measure stroke severity. The NIHSS includes the following domains: level of consciousness, eye movements, integrity of visual fields, facial movements, arm and leg muscle strength, sensation, coordination, language, speech and neglect. Each impairment is scored on an ordinal scale ranging from 0 to 2, 0 to 3, or 0 to 4. Item scores are summed to a total score ranging from 0 to 42 (the higher the score, the more severe the stroke).

  4. Barthel Index (BI) to evaluate the self-care ability [ Time Frame: 3 months ]
    The Barthel index (BI) is an ordinal scale used to measure performance in activities of daily living (ADL). It uses ten variables describing ADL and mobility including: help needed with grooming, toilet use, feeding, transfers, walking, dressing, climbing stairs, bathing, presence of absence of fecal incontinence and urinary incontinence. Each performance item is rated on this scale with a given number of points from 0 to 10 or 0 to 15. Item scores are summed to a total score ranging from 0 to 100. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence. Totally dependent ranges from 0 to 20, severe dependent ranges from 21 to 60, moderate dependent ranges from 61 to 90, mild dependent ranges from 91 to 99, and 100 indicates completely independent.

  5. Rate of muscle strength level of the hemiplegic limb [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Mortality rate [ Time Frame: 12 months ]
  2. Change in Glasgow coma scale (GCS) score [ Time Frame: 1 month ]
    The Glasgow coma scale (GCS) is based on a 15-point scale for estimating and categorizing the consciousness. The test measures the motor response (1 to 6), verbal response (1 to 5) and eye opening response (1 to 4). The score is determined by the sum of the score in each of the 3 categories, with a maximum score of 15 and a minimum score of 3. A lower number indicating a more severe injury and a poorer prognosis.

  3. Change in Glasgow outcome scale (GOS) score [ Time Frame: 12 months ]
    The Glasgow outcome score (GOS) applies to patients with brain damage allowing the objective assessment of their recovery. This allows a prediction of the long-term course of rehabilitation to return to work and everyday life. Scale consists of five grades from 1 to 5. 1 denotes death. 2 denotes persistent vegetative state.3 denotes severe disability. 4 denotes moderate disability and 5 denotes low disability.

  4. MRI (T1, T2, Flair, DWI) scanning [ Time Frame: 12 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female participants between 30 and 75 years of age, diagnosed of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume from 10 ml to 60 ml calculated by ABC/2 formula.
  • Within 5 days from onset to operation, and no improvement.
  • Glasgow Coma Scale (GCS) score of 9 to 15.
  • With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength≤grade 3.
  • Modified Rankin scale (mRS) score≤1 in past medical history.
  • Women of reproductive age have negative pregnancy tests.
  • The participants or the legal guardian/representative who are suitable and willing to participate in the clinical trial and can cooperate to complete the follow-ups.

Exclusion Criteria:

  • Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation AVM and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage.
  • In the sequela stage of cerebral trauma.
  • Hematoma involves other structures including but not limited to the thalamus and midbrain or complicated with intraventricular hemorrhage.
  • With neurologic impairment before cerebral hemorrhage onset.
  • Participants receiving anticoagulant or antiplatelet therapy.
  • The disease progresses quickly. Manifestation of cerebral herniation such as bilateral dilated pupil, disappearance of light reflex, and unstable vital signs.
  • Active stage of infectious diseases including but not limited to HIV, hepatitis B, and C.
  • History of poorly controlled seizures.
  • History of severe co-morbidity (including but not limited to hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment. Coagulation dysfunction INR >1.4, PTT>37 seconds, thrombocytopenia (PLT<8×10^9/L), serum creatinine exceeded the upper limit of normal by 1.4 times, serum ALT >150U/L, and/or serum total bilirubin >1.6mg/dl.
  • Participants with a mechanical heart valve. Biological valves are acceptable.
  • Participants with a risk of embolism (including but not limited to a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable.
  • May be pregnant in the near future or already pregnant.
  • Enrolled in this clinical trial or participating in other interventional medical research or clinical trials at the same time.
  • Participants difficult to follow up or with poor compliance due to various reasons (including but not limited to geographical and social factors, drug or alcohol abuse).
  • Participants or the legal guardian/representative is unable or unwilling to give the written informed consent.
  • Vulnerable groups (including but not limited to mental retardation, abuse, inability to fully exercise informed consent).
  • Any subject that the researchers think is not suitable for enrollment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04074408


Contacts
Layout table for location contacts
Contact: Jianmin Zhang, Doctor 86-13805722695 2307010@zju.edu.cn

Locations
Layout table for location information
China, Zhejiang
Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
Hangzhou, Zhejiang, China, 310009
Contact: Jianmin Zhang, Doctor    86-13805722695    2307010@zju.edu.cn   
Sponsors and Collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
The First Affiliated Hospital, University of Science and Technology of China
Huzhou Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Fujian Medical University
Jinhua Hospital, School of Medicine, Zhejiang University
Taizhou Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier: NCT04074408    
Other Study ID Numbers: SAHZJU-hUMSCs
First Posted: August 30, 2019    Key Record Dates
Last Update Posted: May 26, 2020
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ganglion Cysts
Synovial Cyst
Basal Ganglia Hemorrhage
Hematoma
Cysts
Neoplasms
Mucinoses
Connective Tissue Diseases
Hemorrhage
Pathologic Processes
 Basal Ganglia Cerebrovascular Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebrovascular Disorders
Cerebral Hemorrhage
Intracranial Hemorrhages
Vascular Diseases
Cardiovascular Diseases